Aarti Drugs Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/a27imzk2ifcfy7dq5d8ldn5i.pdf

Key Takeaways


Revenue & Volume: The Export Drag

Harit Pragji Shah: "Export for the Q2 also we subdued demand as of now. And moreover, there is freight rates have just moved up again like COVID levels -- some containers are not available, and all that situation is there. So it's not related to Red Sea actually, but some other things. So overall, we feel Q2 will be similar to Q1 in exports and the demand will start coming up from Q3, it looks like as of now."

Margins: Gross Margin Progress, Operating Leverage Pain

Adhish Patil: "The main problem what happened this particular quarter was lack in volumes."
Adhish Patil: "What we feel, had our volumes being decently good, probably we would have achieved around -- at least 14% EBITDA margin for this quarter, if our volumes were good."

Capacity Expansion: The H2 Growth Engine


Specialty Chemicals & New Products


Pricing & Rate Variance

Adhish Patil: "So basically, the export which happened in March quarter those are the orders taken in the December quarter when the prices were high. So those orders got executed in March quarter."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetUpwards of ₹4,000 crores (assumes current prices)FY27
API volume growthHigh single-digit full year; H1 flattish, H2 mid-teens YoYFY25
Specialty chemicals growth50% YoY growth in H2, driven by Saykha projectH2 FY25
Standalone gross marginReach ~35% (from ~34.1% currently), demand-dependentNo fixed date
Saykha greenfield projectCommence operationsEnd of Q2 FY25
Baddi brownfield expansionIncrease capacity 15-20% in the next quarter; nearly double over 12-15 monthsQ2 FY25 / FY26
Dermatology facility ramp-upProgressive production ramp-upNext two quarters
Oncology product launchesInitial sales from FY26, majority from FY27FY26-FY27
Export demand recoveryDemand expected to pick upFrom Q3 FY25
Negative rate varianceVariance disappears as base resetsH2 FY25

Key Metrics

MetricQ1 FY25
Revenue₹557 cr, down 16% YoY; 11% of decline from negative price variance
EBITDA₹66 cr, with EBITDA margin at 11.9%
PAT₹33 cr
Gross margin (standalone)34.1%, improved vs March 2024 quarter; target of ~35%
Formulation segment revenue₹70.4 cr, up 4.2% QoQ
Formulation exports share57% of total formulations revenue
API export volume changeDown ~8% YoY
API domestic price varianceDown a little upwards of 12% YoY
API export price varianceDown ~9% YoY
Dermatology scale-up impact₹6 cr negative impact at PBT level; ₹3.5 cr at EBITDA, ₹2.5 cr post-EBITDA
Capex incurred during quarter₹52 cr, mainly towards capacity expansion, backward integration, and new formulation launches
Full-year capex guidance₹200 cr, funded through internal accruals and partly through term loans
FY27 revenue guidanceUpwards of ₹4,000 cr, assuming current prices
Specialty Chemicals H2 growth expectation50% YoY growth in second half of FY25
Metformin capacity1,400–1,500 tons per month, increasing to 1,700–1,800 tons per month
Oncology peak revenue budget₹300–400 cr, over next 2–3 years